Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.
Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V; Immunotherapy Subcommittee of Acute Leukemia Working Party. Spyridonidis A, et al. Leukemia. 2012 Jun;26(6):1211-7. doi: 10.1038/leu.2011.351. Epub 2012 Jan 31. Leukemia. 2012. PMID: 22290066
Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia.
Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N, Finke J, Spyridonidis A. Themeli M, et al. Among authors: spyridonidis a. Leukemia. 2010 Mar;24(3):536-43. doi: 10.1038/leu.2009.284. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072151
Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet.
Lagadinou ED, Marangos M, Liga M, Panos G, Tzouvara E, Dimitroulia E, Tiniakou M, Tsakris A, Zoumbos N, Spyridonidis A. Lagadinou ED, et al. Among authors: spyridonidis a. Transpl Infect Dis. 2010 Oct;12(5):437-40. doi: 10.1111/j.1399-3062.2010.00515.x. Transpl Infect Dis. 2010. PMID: 20561301
Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation.
Kaloyannidis P, Voutiadou G, Baltadakis I, Tsirigotis P, Spyridonidis A, Repousis P, Balta A, Tsimberis S, Karakasis D, Sakellari I, Dervenoulas I, Harhalakis N, Anagnostopoulos A. Kaloyannidis P, et al. Among authors: spyridonidis a. Biol Blood Marrow Transplant. 2012 Mar;18(3):451-7. doi: 10.1016/j.bbmt.2011.07.020. Epub 2011 Jul 29. Biol Blood Marrow Transplant. 2012. PMID: 21803018 Free article.
High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC, Spyridonidis A. Liga M, et al. Among authors: spyridonidis a. Biol Blood Marrow Transplant. 2013 Jan;19(1):75-81. doi: 10.1016/j.bbmt.2012.07.021. Epub 2012 Aug 4. Biol Blood Marrow Transplant. 2013. PMID: 22871557 Free article. Clinical Trial.
137 results